Sign In
Buy AXNX
$70.98
+0 (+0%)
At Close: Feb 13, 2025
Boston Scientific Stock Set to Gain From Completion of Axonics Deal
08:50am, Tuesday, 19'th Nov 2024
BSX's acquisition of Axonics marks its entry into sacral neuromodulation and complements its Urology business.
Boston Scientific Closes Acquisition of Axonics, Inc.
08:43am, Friday, 15'th Nov 2024
MARLBOROUGH, Mass. , Nov. 15, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (Nasdaq: AXNX), a medical technology company
Axonics Modulation Technologies (AXNX) Q3 Earnings and Revenues Top Estimates
06:57pm, Thursday, 07'th Nov 2024
Axonics Modulation Technologies (AXNX) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.08 per share a year
Axonics Shares Fall Despite Australia's Approval for R20 SNM Device
11:30am, Friday, 27'th Sep 2024
AXNX's R20 rechargeable SNM system, offering long-lasting treatment for bladder and bowel dysfunction, gains approval in Australia.
Axonics Receives Regulatory Approval for Fourth-Generation Rechargeable SNM System in Australia
06:00am, Thursday, 26'th Sep 2024
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics R20® r
Axonics Stock Rises on Favorable Verdict in Patent Case With Medtronic
08:55am, Wednesday, 25'th Sep 2024
AXNX stock continues to gain following a favorable court ruling last week in a patent litigation with Medtronic.
Axonics Prevails in Patent Infringement Lawsuit with Medtronic
06:59pm, Wednesday, 18'th Sep 2024
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that the jury has returned a unanimous verdict in the patent infringement lawsuit brought by Medtronic against Axonics in
Axonics Modulation Technologies (AXNX) Surpasses Q2 Earnings and Revenue Estimates
06:26pm, Thursday, 01'st Aug 2024
Axonics Modulation Technologies (AXNX) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to loss of $0.15 per share a year ago
Axonics, Inc. (NASDAQ:AXNX) Shares Sold by Amalgamated Bank
05:01am, Monday, 20'th May 2024
Amalgamated Bank cut its holdings in shares of Axonics, Inc. (NASDAQ:AXNX – Free Report) by 6.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities an
Axonics Receives Regulatory Approval for Recharge-Free SNM System in Australia
04:01pm, Thursday, 16'th May 2024
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics F15™
Axonics Reports First Quarter 2024 Financial Results
04:01pm, Tuesday, 30'th Apr 2024
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops and commercializes innovative and minimally invasive products to treat bladder and bowel dysfu
Boston Scientific Announces Results for First Quarter 2024
06:30am, Wednesday, 24'th Apr 2024
MARLBOROUGH, Mass. , April 24, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.856 billion during the first quarter of 2024, growing 13.8 percent on a reported
FTC seeks more information on Boston Scientific's $3.7 bln Axonics deal
07:54am, Thursday, 04'th Apr 2024
Boston Scientific said on Thursday the U.S. Federal Trade Commission (FTC) has requested additional information from the medical device maker related to its $3.7 billion deal to buy Axonics.
All You Need to Know About Axonics (AXNX) Rating Upgrade to Buy
01:01pm, Friday, 29'th Mar 2024
Axonics (AXNX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Axonics Stockholders Approve Merger Agreement with Boston Scientific
04:01pm, Friday, 22'nd Mar 2024
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) announced that its stockholders have voted today to adopt Axonics' merger agreement with Boston Scientific Corporation (NYSE: BSX). Accord
